Samsung BIoepis announced that it has relaunched Byooviz US marketing efforts with Harrow, the ophthalmology product commercialization partner it signed last July; Lupin receives FDA approval for its own ranibizumab biosimilar. On July 1, Samsung Bioepis announced that the pause in marketing for its ranibizumab biosimilar Byooviz has come to a close, with the relaunch … Continue reading Samsung Bioepis Reboots Byooviz Marketing With Harrow at the Helm